Developing a Guidance Document for Industry on New Therapeutic Agents for Atopic Dermatitis in Children and Adolescents
10 November 2019
Principal Investigator:
Elaine Siegfried, MD – St. Louis University
Overview:
Treatment options are limited for children with atopic dermatitis (AD). This project was a consensus effort to guide clinical development programs of companies developing new therapies for AD in children. The hope that it will provide a valuable framework for efficient development and approval of desperately-needed new therapies.
Status:
This project is complete with a guidance document submitted to the FDA and paper published in Pediatric Dermatology in 2018 (see publications page).
